Sera Prognostics, Inc. (SERA) company profile

Sera Prognostics is a women’s health diagnostics company focused on improving maternal and neonatal outcomes through biomarker discovery. The company combines proteomics and bioinformatics platforms with clinical data to develop blood-based tests and predictive analytic tools. Its primary commercial product is the PreTRM test, a non-invasive blood test administered during weeks 18 through 20 of pregnancy to evaluate the risk of spontaneous preterm birth in women carrying a single fetus. The company's technology platform identifies dynamic protein changes to detect adverse pregnancy conditions.

The company serves expectant mothers, healthcare providers, and insurance payers seeking to assess pregnancy risks and reduce complications. Its proprietary biobank includes demographically and clinically annotated specimens collected from thousands of pregnant women across the United States, supplemented by international research collaborations in Europe, Asia, and Africa. Sera Prognostics is based in the United States and maintains its corporate headquarters in Salt Lake City, Utah.

Summary of the business section of Sera Prognostics's latest annual report, written by StockData.

Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.

“The initial public offering price is $16.00 per share of Class A common stock.”

Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.